[go: up one dir, main page]

MX2023010849A - Métodos de tratamiento. - Google Patents

Métodos de tratamiento.

Info

Publication number
MX2023010849A
MX2023010849A MX2023010849A MX2023010849A MX2023010849A MX 2023010849 A MX2023010849 A MX 2023010849A MX 2023010849 A MX2023010849 A MX 2023010849A MX 2023010849 A MX2023010849 A MX 2023010849A MX 2023010849 A MX2023010849 A MX 2023010849A
Authority
MX
Mexico
Prior art keywords
methods
treatment
subject
irritability
anger
Prior art date
Application number
MX2023010849A
Other languages
English (en)
Inventor
Iain Stewart Mcgregor
Michael Thomas Bowen
Original Assignee
Kinoxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021900789A external-priority patent/AU2021900789A0/en
Application filed by Kinoxis Therapeutics Pty Ltd filed Critical Kinoxis Therapeutics Pty Ltd
Publication of MX2023010849A publication Critical patent/MX2023010849A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee métodos para tratar o prevenir la agresividad, agitación, irritabilidad y/o ira en un sujeto, que comprende administrar, a un sujeto en necesidad de ello, una cantidad terapéuticamente efectiva de un compuesto de la Fórmula (I).
MX2023010849A 2021-03-18 2022-03-18 Métodos de tratamiento. MX2023010849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2021900789A AU2021900789A0 (en) 2021-03-18 Methods of treatment
PCT/AU2022/050244 WO2022192964A1 (en) 2021-03-18 2022-03-18 Methods of treatment

Publications (1)

Publication Number Publication Date
MX2023010849A true MX2023010849A (es) 2023-09-21

Family

ID=83321866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010849A MX2023010849A (es) 2021-03-18 2022-03-18 Métodos de tratamiento.

Country Status (11)

Country Link
US (1) US20240139206A1 (es)
EP (1) EP4308127A4 (es)
JP (1) JP2024510281A (es)
KR (1) KR20230159492A (es)
CN (1) CN117279647A (es)
AU (1) AU2022240104A1 (es)
BR (1) BR112023018741A2 (es)
CA (1) CA3211786A1 (es)
IL (1) IL305766A (es)
MX (1) MX2023010849A (es)
WO (1) WO2022192964A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3328864T1 (sl) 2015-07-06 2023-02-28 Kinoxis Therapeutics Pty Ltd Terapevtske spojine in sestavki za zdravljenje socialnih motenj in motenj zlorabe substanc

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201015371D0 (en) * 2010-09-14 2010-10-27 Optinose As Nasal delivery
KR20140124465A (ko) * 2013-04-17 2014-10-27 인제대학교 산학협력단 사회 정서 관련 행동 조절을 위한 비강용 옥시토신의 용도
SI3328864T1 (sl) * 2015-07-06 2023-02-28 Kinoxis Therapeutics Pty Ltd Terapevtske spojine in sestavki za zdravljenje socialnih motenj in motenj zlorabe substanc
KR102561721B1 (ko) * 2016-12-12 2023-07-28 키녹시스 테라퓨틱스 피티와이 리미티드 비펩티드성 옥시토신 수용체 작용제
CN114502170A (zh) * 2019-09-06 2022-05-13 金奥克斯治疗有限公司 阿片类药物戒断的治疗

Also Published As

Publication number Publication date
KR20230159492A (ko) 2023-11-21
IL305766A (en) 2023-11-01
AU2022240104A1 (en) 2023-10-05
BR112023018741A2 (pt) 2023-10-24
JP2024510281A (ja) 2024-03-06
EP4308127A4 (en) 2025-01-01
US20240139206A1 (en) 2024-05-02
EP4308127A1 (en) 2024-01-24
WO2022192964A1 (en) 2022-09-22
CN117279647A (zh) 2023-12-22
CA3211786A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CL2020003330A1 (es) Moléculas de ácido nucleico para la reducción de arnm de papd5 o papd7 para tratar la infección por hepatitis b (divisional solicitud no. 3561-2018)
ECSP21080528A (es) Compuestos antivirales que contienen nitrilo
EA202190630A1 (ru) Способы комбинированной терапии
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
CL2022000214A1 (es) Inhibidores de enzimas
CO2022000270A2 (es) Inhibidores de enzimas
MX2023010849A (es) Métodos de tratamiento.
MX2019001412A (es) Compuestos de 9-aminometil minociclina y usos de los mismos.
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
AR128711A1 (es) Métodos para tratar carcinoma microcítico de pulmón
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
MX2022010963A (es) El compuesto 67a (2301085-06-1) inhibidor de rad51 en una dosificación específica para el tratamiento de cáncer.
AR131842A1 (es) Métodos para tratar gliomas
UY39593A (es) Tratamiento para tumores sólidos malignos
MX2019006941A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor.
EA202190125A1 (ru) ПРОИЗВОДНЫЕ ПИРИДОПИРИМИДИНОНА ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl